AnaptysBio (ANAB) Competitors

AnaptysBio (NASDAQ:ANAB) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.

Which has more risk & volatility, ANAB or XENE?

AnaptysBio has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.

Does the MarketBeat Community believe in ANAB or XENE?

Xenon Pharmaceuticals received 55 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 69.79% of users gave Xenon Pharmaceuticals an outperform vote while only 66.37% of users gave AnaptysBio an outperform vote.

Company	Underperform	Outperform
AnaptysBio	Outperform Votes 377 66.37%	Underperform Votes 191 33.63%
Xenon Pharmaceuticals	Outperform Votes 432 69.79%	Underperform Votes 187 30.21%

Which has better earnings and valuation, ANAB or XENE?

AnaptysBio has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$111.87M	5.39	-$163.62M	-$4.85	-4.23
Xenon Pharmaceuticals	$7.50M	311.64	-$182.39M	-$3.23	-9.43

Do insiders and institutionals hold more shares of ANAB or XENE?

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 33.5% of AnaptysBio shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is ANAB or XENE more profitable?

Xenon Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Xenon Pharmaceuticals' return on equity of -24.69% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-289.75%	-287.94%	-37.25%
Xenon Pharmaceuticals	N/A	-24.69%	-23.68%

Do analysts rate ANAB or XENE?

AnaptysBio presently has a consensus target price of $35.88, indicating a potential upside of 74.79%. Xenon Pharmaceuticals has a consensus target price of $54.82, indicating a potential upside of 79.97%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.70
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor ANAB or XENE?

In the previous week, Xenon Pharmaceuticals had 42 more articles in the media than AnaptysBio. MarketBeat recorded 48 mentions for Xenon Pharmaceuticals and 6 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.51 beat Xenon Pharmaceuticals' score of 0.49 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xenon Pharmaceuticals	14 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xenon Pharmaceuticals beats AnaptysBio on 13 of the 19 factors compared between the two stocks.